Sugi Predict

Sugi Predict / Compounds / SCHEMBL250810

SCHEMBL250810

SCHEMBL250810

CC(C)(C)c1ccc(C=O)cn1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.46
▸ CYP2A6 P11509 3/20 0.43
▸ ALDH1A1 P00352 7/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ KCNJ1 P48048 1/20 0.39
▸ ALDH3A1 P30838 1/20 0.36
▸ ALDH1A3 P47895 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ EPHX2 P34913 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.35
▸ TYR P14679 1/20 0.34
▸ CYP2A13 Q16696 1/20 0.34
▸ FDPS P14324 1/20 0.34
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956911 1.00 KDM4E (0.46) KDM4ECYP2A6ALDH1A1NPSR1TRPV1
SCHEMBL2555659 0.84 KDM4E (0.40) KDM4ECYP2A6ALDH1A1NPSR1TRPV1
SCHEMBL932830 0.84 ALDH1A1 (0.40) KDM4ECYP2A6ALDH1A1NPSR1L3MBTL1
SCHEMBL30971683 0.84 KDM4E (0.40) KDM4ECYP2A6ALDH1A1NPSR1TRPV1
SCHEMBL30798672 0.84 ALDH1A1 (0.40) KDM4ECYP2A6ALDH1A1NPSR1L3MBTL1
SCHEMBL20304488 0.81 CYP2A6 (0.38) KDM4ECYP2A6ALDH1A1NPSR1L3MBTL1
SCHEMBL20304829 0.81 KDM4E (0.41) KDM4ECYP2A6ALDH1A1NPSR1L3MBTL1
SCHEMBL7996261 0.81 ALDH1A1 (0.40) KDM4ECYP2A6ALDH1A1L3MBTL1KCNJ1
SCHEMBL20304772 0.80 CHRNA7 (0.45) KDM4ECYP2A6ALDH1A1NPSR1L3MBTL1
SCHEMBL336320 0.79 TRPV4 (0.52) KDM4EALDH1A1TRPV1L3MBTL1KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358929-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2025-07-15 — — US disclosed
US-20250114374-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. 2025-04-10 — — US disclosed
US-20240294546-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2024-09-05 — — US disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 — — US disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 — — US disclosed
EP-3558318-B1 NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-12-20 — — EP disclosed
US-11807650-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2023-11-07 — — US disclosed
US-11807650-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2023-11-07 — — US disclosed
US-11807650-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2023-11-07 — — US disclosed
WO-2023122000-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. (US) 2023-06-29 — — WO disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 — — EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 — — EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 — — EP disclosed
US-20060030618-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2006-02-09 — — US disclosed
US-20050272931-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-12-08 — — US disclosed
EP-1463714-A4 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC (US) 2005-10-19 — — EP disclosed
US-20050227986-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-10-13 — — US disclosed
EP-1463714-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2004-10-06 — — EP disclosed
US-20030195201-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2003-10-16 — — US disclosed
WO-2003049702-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2003-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272931-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 4114/4885CYP2A6 2460/4885ALDH1A1 3238/4885
US-20060030618-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 4114/4885CYP2A6 2460/4885ALDH1A1 3238/4885
US-20250114374-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L10 KDM4E 393/4885CYP2A6 2168/4885ALDH1A1 3831/4885
US-20030195201-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 4024/4885CYP2A6 2419/4885ALDH1A1 3105/4885
US-11807650-B2 NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C KDM4E 1415/4885CYP2A6 1457/4885ALDH1A1 2036/4885
US-20050227986-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 4114/4885CYP2A6 2460/4885ALDH1A1 3238/4885
US-20240294546-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2C KDM4E 1415/4885CYP2A6 1457/4885ALDH1A1 2036/4885
US-12358929-B2 NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C KDM4E 1415/4885CYP2A6 1457/4885ALDH1A1 2036/4885
US-11917901-B2 Metal complexes MCOLN2, MCOLN1, AP1M1 KDM4E 4260/4885CYP2A6 4244/4885ALDH1A1 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.